Highlights of weekly biotech stock moves

Avanir Pharmaceuticals Inc. (NASDAQ:AVNR) gained $0.09 to $3.29 on Friday after EMA's CHMP backed an MAA for Nuedexta dextromethorphan/quinidine to treat pseudobulbar affect (PBA). The company markets the product in the U.S. for PBA, which is characterized by involuntary episodes of laughing and/or crying. The stock gained $0.29 (10%) for the week.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) was down $2.26 to $63.18 last week after submitting an MAA to EMA for Vimizim elosulfase alfa to treat mucopolysaccharidosis IVA (MPS-IVA, Morquio's syndrome). A BLA for the product, submitted in March, is under FDA review...